Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI
Table 1
Patient characteristics at the time of pretreatment MRI as well as treatment characteristics.
Age (years)
61 (53–66)
Age (female) (years)
59 (56–68)
Age (male) (years)
61 (52–63)
Sex
Male
24 (77%)
Female
7 (23%)
HCV genotype
1
24 (77%)
3
2 (7%)
4
5 (16%)
Cirrhosis
27 (87%)
CP stage A
19 (70%)
CP stage B
8 (30%)
MELD points
9 (8–11)
History of variceal bleeding
0 (0%)
Varices
14 (52%)
Small
10 (37%)
Large
4 (15%)
Platelet count (G × L−1)
104 (77–146)
Albumin (g × L−1)
39.6 (35.7–41.8)
Bilirubin (mg × dL−1)
0.92 (0.64–1.48)
Prothrombin time (%)
77 (64.3–86.3)
Treatment-experienced
22 (71%)
Treatment regimen
SOF/SMV
6 (19%)
SOF/DCV
19 (61%)
SOF/LDV
5 (16%)
Treatment duration
12 weeks
10 (32%)
16 weeks
5 (16%)
20 weeks
2 (6%)
24 weeks
14 (45%)
Referring only to patients with cirrhosis. HCV: hepatitis C virus; CP: Child-Pugh score; MELD: model for end-stage liver disease; SOF: sofosbuvir; SMV: simeprevir; DCV: daclatasvir; LDV: ledipasvir.
